20:47 , May 2, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Tumor mutations of 22 genes could help diagnose prostate cancer, and mutations in two of them could help predict patient outcomes. Whole-genome sequencing of 112 primary and metastatic prostate cancer and matched...
16:20 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Genetic disorders Patient sample and mouse studies suggest inhibiting COL6A1 could help treat hyaline fibromatosis syndrome (HFS), which is caused by ANTXR2 mutations. In patients, levels of COL6A1 were higher in HFS skin nodules...
08:00 , Mar 8, 2012 |  BC Innovations  |  Targets & Mechanisms

A TEM to kill

Novartis AG and the National Cancer Institute have developed mAbs against anthrax toxin receptor 1 that inhibit tumor angiogenesis in multiple mouse models of cancer with fewer side effects than anti-VEGF therapies. 1 A key...
01:09 , Oct 13, 2007 |  BC Extra  |  Clinical News

Dual-action anthrax antitoxin and vaccine

Researchers from the Scripps Research Institute and the Salk Institute for Biological Studies reported in PLoS Pathogens the development of a reagent with combined anthrax antitoxin and vaccine functions. Chimeric virus like particles (VLPs) were...